LLY compared with PLRX: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

PLRXPliant Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

PLRXPliant Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

PLRX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±55.4%▲+3.88%×0.07

= impliedLLY realized, solidPLRX realized, hatchedOne scale, both sides: full bar = 56%× = |realized| ÷ impliedSource: market data

LLYELI Lilly & Co

1,362.58▼−0.16%

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

PLRXPliant Therapeutics, Inc.

0.81▼−1.05%

Regular sessionNov 6 '26

Mkt cap$50.5MRevenue$248,000Q2 FY23Revenue—

Compare

Regular sessionNov 6 '26

LLYELI Lilly & Co

PLRXPliant Therapeutics, Inc.

1,362.58▼−0.16%

Price

0.81▼−1.05%

$1.2T

Mkt cap

$50.5M

Q3 FY26$24.4B

Revenue

$248,000Q2 FY23

FY25$65.2B

Revenue

—

LLY1,362.58▼−0.16%vsPLRX0.81▼−1.05%Regular sessionNov 6 '26